SEARCH

SEARCH BY CITATION

References

  • 1
    Adams PC, Reboussin DM, Barton JC, et al. Hemochromatosis and Iron-Overload Screening in a Racially Diverse Population. N Eng J Med 2005; 352: 176978.
  • 2
    Feder JN, Gnirke A, Thomas W, et al. A novel MHC class I-like gene is mutated in patients with hereditary hemochromatosis. Nat Genet 1996; 13: 399408.
  • 3
    Asberg A, Hveem K, Kruger O, Bjerve K. Persons with screening-detected haemochromatosis: as healthy as the general population? Scand J Gastroenterol 2002; 37: 71924.
  • 4
    Beutler E, Felitti V, Koziol J, Ho N, Gelbart T. Penetrance of the 845G to A (C282Y) HFE hereditary haemochromatosis mutation in the USA. Lancet 2002; 359: 2118.
  • 5
    Adams PC, Deugnier Y, Moirand R, Brissot P. The relationship between iron overload, clinical symptoms and age in 410 patients with genetic hemochromatosis. Hepatology 1997; 25: 1626.
  • 6
    O'Neil J, Powell LW. Clinical aspects of hemochromatosis. Sem Liv Disease 2005; 25: 38191.
  • 7
    Crawford D, Fletcher L, Hubscher S, et al. Patient and graft survival after liver transplantation for hereditary hemochromatosis: implications for pathogenesis. Hepatology 2004; 39: 165562.
  • 8
    Kowdley K, Brandhagen D, Gish R, et al. Survival after liver transplantation in patients with hepatic iron overload: the national hemochromatosis transplant registry. Gastroenterology 2005; 129: 494503.
  • 9
    Adams PC, Alanen K, Preshaw R, et al. Transplantation of haemochromatosis liver and intestine into a normal recipient. Gut 1999; 45: 783.
  • 10
    Adams PC. Hepatocellular carcinoma in hereditary hemochromatosis. Can J Gastroenterol 1993; 7: 3741.
  • 11
    Pietrangelo A. Non-HFE hemochromatosis. Sem Liv Disease 2005; 25: 45060.
  • 12
    Adams PC. Hemochromatosis case definition – out of focus? Nat Clin Gastroenterol Hepatol 2006; 3: 1789.
  • 13
    Tavill AS. Diagnosis and management of hemochromatosis. Hepatology 2001; 33: 13218.
  • 14
    Tavill A, Adams PC. A diagnostic approach to hemochromatosis. Can J Gastro 2006; (in press).
  • 15
    Beutler E, Felitti V, Gelbart T, Ho N. The effect of HFE genotypes on measurement of iron overload in patients attending a health appraisal clinic. Ann Int Med 2000; 133: 32937.
  • 16
    Adams PC, Kertesz AE, McLaren C, Barr R, Bamford A, Chakrabarti S. Population screening for hemochromatosis: a comparison of unbound iron binding capacity, transferrin saturation and C282Y genotyping in 5211 voluntary blood donors. Hepatology 2000; 31: 11604.
  • 17
    Hickman P, Hourigan L, Powell LW, et al. Automated measurement of unsaturated iron binding capacity is an effective screening strategy for C282Y homozygous hemochromatosis. Gut 2000; 46: 4059.
  • 18
    Adams P, Zaccaro D, Moses G, et al. Comparison of the unsaturated iron binding capacity with transferrin saturation as a screening test to detect C282Y homozygotes for hemochromatosis in 101 168 participants in the HEIRS study. Clin Chem 2005; 51: 104851.
  • 19
    Wong K, Adams PC. The diversity of liver diseases associated with an elevated serum ferritin. Can J Gastro 2006; (in press).
  • 20
    Moirand R, Jouanolle A-M, Brissot P, Le Gall J-Y, David V, Deugnier Y. Phenotypic expression of HFE mutations: a French study of 1110 unrelated iron-overloaded patients and relatives. Gastroenterology 1999; 116: 3727.
  • 21
    Rossi E, Olynyk J, Cullen D, et al. Compound heterozygous hemochromatosis genotype predicts increased iron and erythrocyte indices in women. Clin Chem 2000; 46: 1626.
  • 22
    Roetto A, Bosio S, Gramaglia E, Barilaro M, Zecchina G, Camaschella C. Pathogenesis of hyperferritinemia cataract syndrome. Blood Cell Mol Dis 2002; 29: 5325.
  • 23
    Guyader D, Jacquelinet C, Moirand R, et al. Non-invasive prediction of fibrosis in C282Y homozygous hemochromatosis. Gastroenterology 1998; 115: 92936.
  • 24
    Beaton M, Guyader D, Deugnier Y, Moirand R, Chakrabarti S, Adams P. Non-invasive prediction of cirrhosis in C282Y-linked hemochromatosis. Hepatology 2002; 36: 6738.
  • 25
    Adams PC, Speechley M, Kertesz AE. Long-term survival analysis in hereditary hemochromatosis. Gastroenterology 1991; 101: 36872.
  • 26
    Niederau C, Fischer R, Purschel A, Stremmel W, Haussinger D, Strohmeyer G. Long-term survival in patients with hereditary hemochromatosis. Gastroenterology 1996; 110: 110719.
  • 27
    Gandon Y, Olivie D, Guyader D, et al. Non-invasive assessment of hepatic iron stores by MRI. Lancet 2004; 363: 35760.
  • 28
    Alustiza J, Artetxe J, Castiella A, et al. MR Quantification of hepatic iron concentration. Radiology 2004; 230: 47984.
  • 29
    St Pierre T, Clark P, Chua-anusorn W, et al. Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance. Blood 2005; 105: 85561.
  • 30
    Nielsen P, Engelhardt R, Dullman J, Fischer R. Non-invasive liver iron quantification by SQUID-biosusceptometry and serum ferritin iron as new diagnostic parameters in hereditary hemochromatosis. Blood Cells Mol Dis 2002; 29: 4518.
  • 31
    Aguilar-Martinez P, Bismuth M, Picot M, et al. Variable phenotypic presentation of iron overload in H63D homozygotes: are gene modifiers the cause? Gut 2001; 6: 83642.
  • 32
    Asberg A, Hveem K, Thorstensen K, et al. Screening for hemochromatosis – high prevalence and low morbidity in an unselected population of 65 238 persons. Scand J Gastroenterol 2001; 36: 110815.
  • 33
    Barash C. Genetic discrimination and screening for hemochromatosis: then and now. Genetic Testing 2000; 4: 2138.
  • 34
    Hall M, McEwen J, Barton J, et al. Concerns in a primary care population about genetic discrimination by insurers. Genet Med 2005; 7: 3116.
  • 35
    Delatycki M, Allen K, Nisselle A, et al. Use of community genetic screening to prevent HFE-associated hereditary hemochromatosis. Lancet 2005; 366: 316.
  • 36
    Shaheen N, Lawrence L, Bacon B, et al. Insurance, employment, and psychosocial consequences of a diagnosis of hereditary hemochromatosis in subjects without end-organ damage. Am J Gastroenterol 2003; 98: 117580.
    Direct Link:
  • 37
    Power T, Adams PC. Psychosocial impact of genetic screening for hemochromatosis in population screening and referred patients. Genetic Testing 2001; 5: 10710.
  • 38
    Pietrangelo A. Non-HFE hemochromatosis. Hepatology 2004; 39: 2129.
  • 39
    Pietrangelo A. Hereditary hemochromatosis: a new look at an old disease. N Eng J Med 2004; 350: 238397.
  • 40
    Kotze M, DeVillers J, Bouwens C, et al. Molecular diagnosis of hereditary hemochromatosis: application of a newly-developed reverse-hybridization assay in the South African population. Clin Genet 2004; 65: 31721.
  • 41
    Adams PC, Chakrabarti S. Genotypic/phenotypic correlations in genetic hemochromatosis: evolution of diagnostic criteria. Gastroenterology 1998; 114: 31923.
  • 42
    Yamashita C, Adams PC. Natural history of the C282Y homozygote of the hemochromatosis gene (HFE) with a normal serum ferritin level. Clin Gastroenterol Hepatol 2003; 1: 38891.
  • 43
    Beutler E. Natural history of hemochromatosis. Mayo Clin Proc 2004; 79: 3056.
  • 44
    Olynyk J, Hagan S, Cullen D, Beilby J, Whittall D. Evolution of untreated hereditary hemochromatosis in the Busselton population: a 17-year study. Mayo Clin Proc 2004; 79: 30913.
  • 45
    Andersen R, Tybjaerg-Hansen A, Appleyard M, Birgens H, Nordestgaard B. Hemochromatosis mutations in the general population: iron overload progression rate. Blood 2004; 103: 29149.
  • 46
    Gleeson F, Ryan E, Barrett S, Crowe J. Clinical expression of haemochromatosis in Irish C282Y homozygotes identified through family screening. Eur J Gastroenterol Hepatol 2004; 16: 85963.
  • 47
    Adams P, Acton R, Walker A. A primer for predicting risk of disease in HFE-linked hemochromatosis. Genetic Testing 2001; 5: 3116.
  • 48
    Adams PC, Kertesz AE, Valberg LS. Rate of iron reaccumulation following iron depletion in hereditary hemochromatosis. Implications for venesection therapy. J Clin Gastroenterol 1993; 16: 20710.
  • 49
    Adams PC. Factors affecting rate of iron mobilization during venesection therapy for hereditary hemochromatosis. Am J Hematology 1998; 58: 1619.
  • 50
    Leitman S, Browning J, Yau Y, et al. Hemochromatosis subjects as allogeneic blood donors: a prospective study. Transfusion 2003; 43: 153844.
  • 51
    Wojcik J, Speechley M, Kertesz A, Chakrabarti S, Adams P. Natural history of C282Y homozygotes for haemochromatosis. Can J Gastro 2002; 16: 297302.
  • 52
    Olsson K, Vaisanen M, Konar J, Bruce A. The effect of withdrawal of food iron fortification in Sweden as studied with phlebotomy in subjects with genetic hemochromatosis. Eur J Clin Nutr 1998; 51: 7826.
  • 53
    Adams PC, Passmore L, Chakrabarti S, et al. Liver diseases in the hemochromatosis and iron overload screening study. Clin Gastroenterol Hepatol 2006; epub: http://www.pulsus.com/WCOG/abs/LB.081.htm.
  • 54
    Olynyk J, Cullen D, Aquilia S, Rossi E, Summerville L, Powell LW. A population-based study of the clinical expression of the hemochromatosis gene. N Eng J Med 1999; 341: 71824.
  • 55
    Powell L, Dixon J, Ramm G, et al. Screening for hemochromatosis in asymptomatic subjects with or without a family history. Arch Int Med 2006; 166: 294301.